These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 6817151)

  • 21. Laboratory response to intranasal desmopressin in women with menorrhagia and platelet dysfunction.
    Rose SS; Faiz A; Miller CH; Saidi P; Philipp CS
    Haemophilia; 2008 May; 14(3):571-8. PubMed ID: 18312366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The effect of 1-deamino-8-D-arginine vasopressin (DDAVP) on blood coagulation in patients with hemophilia A and in healthy men].
    Blättler W; Jacky E; Müller M; Graf M
    Schweiz Med Wochenschr; 1979 Sep; 109(37):1367-8. PubMed ID: 314661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [DDAVP administration in a case of congenital combined factor V and factor VIII deficiency].
    Takai Y; Hayashi H; Ishimaru F; Fujita T; Tsurumi N; Tsuda T; Kimura I
    Rinsho Ketsueki; 1989 Nov; 30(11):2035-40. PubMed ID: 2607619
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Absent factor VIII response to synthetic vasopressin analogue (DDAVP) in nephrogenic diabetes insipidus.
    Kobrinsky NL; Doyle JJ; Israels ED; Winter JS; Cheang MS; Walker RD; Bishop AJ
    Lancet; 1985 Jun; 1(8441):1293-4. PubMed ID: 2860491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Bleeding tendency in chronic kidney failure with hemodialysis].
    Takahashi H; Shibata A
    Nihon Rinsho; 1992 Jan; 50 Suppl():771-7. PubMed ID: 1578765
    [No Abstract]   [Full Text] [Related]  

  • 26. Subcutaneous desmopressin (DDAVP) shortens the bleeding time in uremia.
    Viganò GL; Mannucci PM; Lattuada A; Harris A; Remuzzi G
    Am J Hematol; 1989 May; 31(1):32-5. PubMed ID: 2705441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of DDAVP in inherited and acquired platelet dysfunction.
    DiMichele DM; Hathaway WE
    Am J Hematol; 1990 Jan; 33(1):39-45. PubMed ID: 2293761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [DDAVP and its effect on factor VIII activity (author's transl)].
    Sikorová J; Vorlová Z
    Cas Lek Cesk; 1981 May; 120(18):553-6. PubMed ID: 6794913
    [No Abstract]   [Full Text] [Related]  

  • 29. Subcutaneous desmopressin (DDAVP) shortens the prolonged bleeding time in patients with liver cirrhosis.
    Cattaneo M; Tenconi PM; Alberca I; Garcia VV; Mannucci PM
    Thromb Haemost; 1990 Nov; 64(3):358-60. PubMed ID: 2096487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [New treatment possibilities for hemophiliacs. International symposium "DDAVP in Bleeding Disorders", Münster, 16-17 March 1979].
    Sutor AH
    Med Klin; 1979 Jul; 74(28-29):2-3. PubMed ID: 39231
    [No Abstract]   [Full Text] [Related]  

  • 31. [The position of a vasopressin derivative ("DDAVP") in the treatment of haemophilia A (author's transl)].
    Blättler W; Jacky E; Müller M; Graf M; Meili E
    Ther Umsch; 1979 Apr; 36(4):330-3. PubMed ID: 377557
    [No Abstract]   [Full Text] [Related]  

  • 32. Factor VIII-related activities after 1-deamino-8-D-arginine vasopressin in multicentric reticulohistiocytosis.
    Taddeo U; Trotta F; Menegale G; Ballerini G
    Ric Clin Lab; 1984; 14(1):37-9. PubMed ID: 6427880
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Uremic plasma after infusion of desmopressin (DDAVP) improves the interaction of normal platelets with vessel subendothelium.
    Escolar G; Cases A; Monteagudo J; Garrido M; Lopez J; Ordinas A; Revert L; Castillo R
    J Lab Clin Med; 1989 Jul; 114(1):36-42. PubMed ID: 2738447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Desmopressin (dDAVP): a powerful general hemostatic agent?
    Drouet L; Scrobohaci ML; Boudaoud S; Vilain G
    Nouv Rev Fr Hematol (1978); 1989; 31(2):163-5. PubMed ID: 2528120
    [No Abstract]   [Full Text] [Related]  

  • 35. Experience of desmopressin (DDAVP) administration in patients with congenital and acquired bleeding disorders.
    Tsay W; Shen MC
    J Formos Med Assoc; 1992 Oct; 91(10):962-9. PubMed ID: 1362675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 1-Deamino-8-D-arginine-vasopressin--an alternative in the management of mild haemophilia A and von Willebrand's disease.
    Niessner H; Korninger C
    Wien Klin Wochenschr; 1983 Nov; 95(21):753-7. PubMed ID: 6424339
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DDAVP (1-desamino-8-D-arginine-vasopressin) treatment of central diabetes insipidus--mechanism of prolonged antidiuresis.
    Seif SM; Zenser TV; Ciarochi FF; Davis BB; Robinson AG
    J Clin Endocrinol Metab; 1978 Mar; 46(3):381-8. PubMed ID: 221517
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical experience with deamino-8-D-AGR-Vasopressin (DDAVP) in patients with Factor VIII deficiency.
    Sweeney JD; Crosby P; McCann SR; Temperley IJ
    Ir J Med Sci; 1981 Aug; 150(8):236-9. PubMed ID: 6974718
    [No Abstract]   [Full Text] [Related]  

  • 40. Response of factor XII to DDAVP in patients with Hageman factor deficiency.
    Gamba G; Grignani G; Longoni P; Ascari E
    Br J Haematol; 1983 Dec; 55(4):713-5. PubMed ID: 6422975
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.